Rui Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rui Chen has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Yanling She
Guangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangdong Second Provincial General Hospital, 466 Xin Gang Zhong Road, Guangzhou 510317, China
16 shared publicationsShanyao Zhou
Guangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangdong Second Provincial General Hospital, 466 Xin Gang Zhong Road, Guangzhou 510317, China
15 shared publicationsHuacai Shi
Guangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangdong Second Provincial General Hospital, 466 Xin Gang Zhong Road, Guangzhou 510317, China
12 shared publicationsSi Lei
Guangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangdong Second Provincial General Hospital, 466 Xin Gang Zhong Road, Guangzhou 510317, China
10 shared publicationsCheng Li
Guangdong Second Provincial General Hospital, Guangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangzhou, China
8 shared publicationsTing Jiang
Guangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangdong Second Provincial General Hospital, Guangzhou, China
6 shared publications
Latest Publications
- 15 September 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Multimedia
- Vol. 26 (15209210) , 3788-3798
Cross-Domain Sample Relationship Learning for Facial Expression Recognition
Cross-domain facial expression recognition is confronted by the problem of the large distribution discrepancy and samples inconsistencies between the source domain and target domain. To solve this problem, we propose a cross-domain sample relationship learning (CSRL) method that explores useful intrinsic sample relationships of two domains to narrow the domain discrepancy. Specifically, during the training stage, we first design inter-domain sample transformers to explore the sample similarity relationships between the source and target domains, and then deploy intra-domain sample transformers to capture the internal similar structure of the samples in each domain. Thus dual sample relationships can be learned to align the cross-domain similar samples and preserve the domain-specific information, which can facilitate both the inter-domain invariant features and intra-domain invariant features learning. Subsequently, we design a joint alignment strategy by simultaneously deploying the feature distribution alignment and cross-domain sample relationship learning. Thus, both local similar samples and global domain distribution of two domains can be well aligned to enhance the generalization ability of the model. Experimental results on several benchmark databases show the superiority of CSRL over some state-of-the-art methods.
- 15 September 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Multimedia
- Vol. 26 (15209210) , 3788-3798
Cross-Domain Sample Relationship Learning for Facial Expression Recognition
Cross-domain facial expression recognition is confronted by the problem of the large distribution discrepancy and samples inconsistencies between the source domain and target domain. To solve this problem, we propose a cross-domain sample relationship learning (CSRL) method that explores useful intrinsic sample relationships of two domains to narrow the domain discrepancy. Specifically, during the training stage, we first design inter-domain sample transformers to explore the sample similarity relationships between the source and target domains, and then deploy intra-domain sample transformers to capture the internal similar structure of the samples in each domain. Thus dual sample relationships can be learned to align the cross-domain similar samples and preserve the domain-specific information, which can facilitate both the inter-domain invariant features and intra-domain invariant features learning. Subsequently, we design a joint alignment strategy by simultaneously deploying the feature distribution alignment and cross-domain sample relationship learning. Thus, both local similar samples and global domain distribution of two domains can be well aligned to enhance the generalization ability of the model. Experimental results on several benchmark databases show the superiority of CSRL over some state-of-the-art methods.
- Open Access
- 25 July 2023
- Published by Elsevier in Journal of Advanced Research
- Vol. 60, 93-110
Hsa_circ_0001402 alleviates vascular neointimal hyperplasia through a miR-183-5p-dependent regulation of vascular smooth muscle cell proliferation, migration, and autophagy
- 25 July 2023
- Published by Elsevier in Journal of Advanced Research
- Vol. 60, 93-110
Open AccessHsa_circ_0001402 alleviates vascular neointimal hyperplasia through a miR-183-5p-dependent regulation of vascular smooth muscle cell proliferation, migration, and autophagy
- 2 October 2022
- Published by Taylor & Francis in Cell Cycle
- Vol. 22 (5) , 495-505
Roles of super enhancers and enhancer RNAs in skeletal muscle development and disease
Skeletal muscle development is a multistep biological process regulated by a variety of myogenic regulatory factors, including MyoG, MyoD, Myf5, and Myf6 (also known as MRF4), as well as members of the FoxO subfamily. Differentiation and regeneration during skeletal muscle myogenesis contribute to the physiological function of muscles. Super enhancers (SEs) and enhancer RNAs (eRNAs) are involved in the regulation of development and diseases. Few studies have identified the roles of SEs and eRNAs in muscle development and pathophysiology. To develop approaches to enhance skeletal muscle mass and function, a more comprehensive understanding of the key processes underlying muscular diseases is needed. In this review, we summarize the roles of SEs and eRNAs in muscle development and disease through affecting of DNA methylation, FoxO subfamily, RAS-MEK signaling, chromatin modifications and accessibility, MyoD and cis regulating target genes. The summary could inform strategies to increase muscle mass and treat muscle-related diseases.
- 2 October 2022
- Published by Taylor & Francis in Cell Cycle
- Vol. 22 (5) , 495-505
Roles of super enhancers and enhancer RNAs in skeletal muscle development and disease
Skeletal muscle development is a multistep biological process regulated by a variety of myogenic regulatory factors, including MyoG, MyoD, Myf5, and Myf6 (also known as MRF4), as well as members of the FoxO subfamily. Differentiation and regeneration during skeletal muscle myogenesis contribute to the physiological function of muscles. Super enhancers (SEs) and enhancer RNAs (eRNAs) are involved in the regulation of development and diseases. Few studies have identified the roles of SEs and eRNAs in muscle development and pathophysiology. To develop approaches to enhance skeletal muscle mass and function, a more comprehensive understanding of the key processes underlying muscular diseases is needed. In this review, we summarize the roles of SEs and eRNAs in muscle development and disease through affecting of DNA methylation, FoxO subfamily, RAS-MEK signaling, chromatin modifications and accessibility, MyoD and cis regulating target genes. The summary could inform strategies to increase muscle mass and treat muscle-related diseases.
- 31 August 2022
- Published by Elsevier in Tissue and Cell
- Vol. 79, 101910
Nec-1 alleviated the deleterious effect of CoCl2 on C2C12 myoblast differentiation and fusion via the mTOR pathway
- 31 August 2022
- Published by Elsevier in Tissue and Cell
- Vol. 79, 101910
Nec-1 alleviated the deleterious effect of CoCl2 on C2C12 myoblast differentiation and fusion via the mTOR pathway
- 16 February 2022
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 148, 293-306
A new perspective on depression and neuroinflammation: Non-coding RNA
- 16 February 2022
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 148, 293-306
A new perspective on depression and neuroinflammation: Non-coding RNA
- Open Access
- 18 August 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Lnc-GD2H Promotes Proliferation by Forming a Feedback Loop With c-Myc and Enhances Differentiation Through Interacting With NACA to Upregulate Myog in C2C12 Myoblasts
In the present study, the roles of a novel long non-coding RNA (lncRNA), lnc-GD2H, in promoting C2C12 myoblast proliferation and differentiation and muscle regeneration were investigated by quantitative polymerase chain reaction, western blotting, Cell Counting Kit-8, 5-ethynyl-2′-deoxyuridine (EdU), immunofluorescence staining, luciferase reporter, mass spectrometry, pulldown, chromatin immunoprecipitation, RNA immunoprecipitation assay, wound healing assays, and cardiotoxin (CTX)-induced muscle injury assays. It was observed that lnc-GD2H promoted myoblast proliferation as evidenced by the enhancement of the proliferation markers c-Myc, CDK2, CDK4, and CDK6, percentage of EdU-positive cells, and rate of cell survival during C2C12 myoblast proliferation. Additional experiments confirmed that c-Myc bound to the lnc-GD2H promoter and regulated its transcription. lnc-GD2H promoted cell differentiation with enhanced MyHC immunostaining as well as increased expression of the myogenic marker genes myogenin (Myog), Mef2a, and Mef2c during myoblast differentiation. Additional assays indicated that lnc-GD2H interacted with NACA which plays a role of transcriptional regulation in myoblast differentiation, and the enrichment of NACA at the Myog promoter was impaired by lnc-GD2H. Furthermore, inhibition of lnc-GD2H impaired muscle regeneration after CTX-induced injury in mice. lnc-GD2H facilitated the expression of proliferating marker genes and formed a feedback loop with c-Myc during myoblast proliferation. In differentiating myoblasts, lnc-GD2H interacted with NACA to relieve the inhibitory effect of NACA on Myog, facilitating Myog expression to promote differentiation. The results provide evidence for the role of lncRNAs in muscle regeneration and are useful for developing novel therapeutic targets for muscle disorders.
- 18 August 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Open AccessLnc-GD2H Promotes Proliferation by Forming a Feedback Loop With c-Myc and Enhances Differentiation Through Interacting With NACA to Upregulate Myog in C2C12 Myoblasts
In the present study, the roles of a novel long non-coding RNA (lncRNA), lnc-GD2H, in promoting C2C12 myoblast proliferation and differentiation and muscle regeneration were investigated by quantitative polymerase chain reaction, western blotting, Cell Counting Kit-8, 5-ethynyl-2′-deoxyuridine (EdU), immunofluorescence staining, luciferase reporter, mass spectrometry, pulldown, chromatin immunoprecipitation, RNA immunoprecipitation assay, wound healing assays, and cardiotoxin (CTX)-induced muscle injury assays. It was observed that lnc-GD2H promoted myoblast proliferation as evidenced by the enhancement of the proliferation markers c-Myc, CDK2, CDK4, and CDK6, percentage of EdU-positive cells, and rate of cell survival during C2C12 myoblast proliferation. Additional experiments confirmed that c-Myc bound to the lnc-GD2H promoter and regulated its transcription. lnc-GD2H promoted cell differentiation with enhanced MyHC immunostaining as well as increased expression of the myogenic marker genes myogenin (Myog), Mef2a, and Mef2c during myoblast differentiation. Additional assays indicated that lnc-GD2H interacted with NACA which plays a role of transcriptional regulation in myoblast differentiation, and the enrichment of NACA at the Myog promoter was impaired by lnc-GD2H. Furthermore, inhibition of lnc-GD2H impaired muscle regeneration after CTX-induced injury in mice. lnc-GD2H facilitated the expression of proliferating marker genes and formed a feedback loop with c-Myc during myoblast proliferation. In differentiating myoblasts, lnc-GD2H interacted with NACA to relieve the inhibitory effect of NACA on Myog, facilitating Myog expression to promote differentiation. The results provide evidence for the role of lncRNAs in muscle regeneration and are useful for developing novel therapeutic targets for muscle disorders.
- Open Access
- 8 July 2021
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 12
Knockdown of CNN3 Impairs Myoblast Proliferation, Differentiation, and Protein Synthesis via the mTOR Pathway
Background: Myogenesis is a complex process that requires optimal outside–in substrate–cell signaling. Calponin 3 (CNN3) plays an important role in regulating myogenic differentiation and muscle regeneration; however, the precise function of CNN3 in myogenesis regulation remains poorly understood. Here, we investigated the role of CNN3 in a knockdown model in the mouse muscle cell line C2C12.Methods: Myoblast proliferation, migration, differentiation, fusion, and protein synthesis were examined in CNN3 knockdown C2C12 mouse muscle cells. Involvement of the mTOR pathway in CNN3 signaling was explored by treating cells with the mTOR activator MHY1485. The regulatory mechanisms of CNN3 in myogenesis were further examined by RNA sequencing and subsequent gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene set enrichment analysis (GSEA).Results: During proliferation, CNN3 knockdown caused a decrease in cell proliferation and migration. During differentiation, CNN3 knockdown inhibited myogenic differentiation, fusion, and protein synthesis in C2C12 cells via the AKT/mTOR and AMPK/mTOR pathways; this effect was reversed by MHY1485 treatment. Finally, KEGG and GSEA indicated that the NOD-like receptor signaling pathway is affected in CNN3 knockdown cell lines.Conclusion: CNN3 may promote C2C12 cell growth by regulating AKT/mTOR and AMPK/mTOR signaling. The KEGG and GSEA indicated that inhibiting CNN3 may activate several pathways, including the NOD-like receptor pathway and pathways involved in necroptosis, apoptosis, and inflammation.
- 8 July 2021
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 12
Open AccessKnockdown of CNN3 Impairs Myoblast Proliferation, Differentiation, and Protein Synthesis via the mTOR Pathway
Background: Myogenesis is a complex process that requires optimal outside–in substrate–cell signaling. Calponin 3 (CNN3) plays an important role in regulating myogenic differentiation and muscle regeneration; however, the precise function of CNN3 in myogenesis regulation remains poorly understood. Here, we investigated the role of CNN3 in a knockdown model in the mouse muscle cell line C2C12.Methods: Myoblast proliferation, migration, differentiation, fusion, and protein synthesis were examined in CNN3 knockdown C2C12 mouse muscle cells. Involvement of the mTOR pathway in CNN3 signaling was explored by treating cells with the mTOR activator MHY1485. The regulatory mechanisms of CNN3 in myogenesis were further examined by RNA sequencing and subsequent gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene set enrichment analysis (GSEA).Results: During proliferation, CNN3 knockdown caused a decrease in cell proliferation and migration. During differentiation, CNN3 knockdown inhibited myogenic differentiation, fusion, and protein synthesis in C2C12 cells via the AKT/mTOR and AMPK/mTOR pathways; this effect was reversed by MHY1485 treatment. Finally, KEGG and GSEA indicated that the NOD-like receptor signaling pathway is affected in CNN3 knockdown cell lines.Conclusion: CNN3 may promote C2C12 cell growth by regulating AKT/mTOR and AMPK/mTOR signaling. The KEGG and GSEA indicated that inhibiting CNN3 may activate several pathways, including the NOD-like receptor pathway and pathways involved in necroptosis, apoptosis, and inflammation.
- Open Access
- 16 December 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (2) , 1
Role of miRNAs and lncRNAs in dexamethasone‑induced myotube atrophy in vitro
Skeletal muscle atrophy is a well‑known adverse effect of long‑term glucocorticoid (GC) therapy. MicroRNAs (miRNAs or miRs) and long non‑coding RNAs (lncRNAs) are important regulators in a number of physiological and pathological processes. However, the role of miRNAs and lncRNAs in the regulation of GC‑treated muscle atrophy remains poorly understood. In the current study, muscular atrophy was induced and the results indicated that C2C12 myotubes were thinner than normal, while the expression of muscle ring finger protein 1 and Atrogin‑1 was increased. The expression of nine miRNAs and seven lncRNAs associated with proliferation and differentiation were analyzed in a dexamethasone (DEX)‑induced muscle atrophy cell model. In addition, the mRNA expression of the downstream targets of lncRNAs that were differentially expressed between DEX‑treated and control cells were determined. The results indicated that the expression of miR‑133a, miR‑133b, miR‑206 and five lncRNAs (increased Atrolnc‑1, Dum, MAR1, linc‑MD1 and decreased Myolinc) were significantly different between the DEX and the control group. Furthermore, the relative mRNA expression of Wnt5a and MyoD was significantly different between the two groups. The results of the current study indicated that some important miRNAs and lncRNAs are associated with DEX‑induced muscle atrophy and have the potential to be further developed as a diagnostic tool for this condition.
- 16 December 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (2) , 1
Open AccessRole of miRNAs and lncRNAs in dexamethasone‑induced myotube atrophy in vitro
Skeletal muscle atrophy is a well‑known adverse effect of long‑term glucocorticoid (GC) therapy. MicroRNAs (miRNAs or miRs) and long non‑coding RNAs (lncRNAs) are important regulators in a number of physiological and pathological processes. However, the role of miRNAs and lncRNAs in the regulation of GC‑treated muscle atrophy remains poorly understood. In the current study, muscular atrophy was induced and the results indicated that C2C12 myotubes were thinner than normal, while the expression of muscle ring finger protein 1 and Atrogin‑1 was increased. The expression of nine miRNAs and seven lncRNAs associated with proliferation and differentiation were analyzed in a dexamethasone (DEX)‑induced muscle atrophy cell model. In addition, the mRNA expression of the downstream targets of lncRNAs that were differentially expressed between DEX‑treated and control cells were determined. The results indicated that the expression of miR‑133a, miR‑133b, miR‑206 and five lncRNAs (increased Atrolnc‑1, Dum, MAR1, linc‑MD1 and decreased Myolinc) were significantly different between the DEX and the control group. Furthermore, the relative mRNA expression of Wnt5a and MyoD was significantly different between the two groups. The results of the current study indicated that some important miRNAs and lncRNAs are associated with DEX‑induced muscle atrophy and have the potential to be further developed as a diagnostic tool for this condition.
- Open Access
- 15 September 2020
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 8
Regulation of Skeletal Muscle Atrophy in Cachexia by MicroRNAs and Long Non-coding RNAs
Skeletal muscle atrophy is a common complication of cachexia, characterized by progressive bodyweight loss and decreased muscle strength, and it significantly increases the risks of morbidity and mortality in the population with atrophy. Numerous complications associated with decreased muscle function can activate catabolism, reduce anabolism, and impair muscle regeneration, leading to muscle wasting. microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), types of non-coding RNAs, are important for regulation of skeletal muscle development. Few studies have specifically identified the roles of miRNAs and lncRNAs in cellular or animal models of muscular atrophy during cachexia, and the pathogenesis of skeletal muscle wasting in cachexia is not entirely understood. To develop potential approaches to improve skeletal muscle mass, strength, and function, a more comprehensive understanding of the known key pathophysiological processes leading to muscular atrophy is needed. In this review, we summarize the known miRNAs, lncRNAs, and corresponding signaling pathways involved in regulating skeletal muscle atrophy in cachexia and other diseases. A comprehensive understanding of the functions and mechanisms of miRNAs and lncRNAs during skeletal muscle wasting in cachexia and other diseases will, therefore, promote therapeutic treatments for muscle atrophy.
- 15 September 2020
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 8
Open AccessRegulation of Skeletal Muscle Atrophy in Cachexia by MicroRNAs and Long Non-coding RNAs
Skeletal muscle atrophy is a common complication of cachexia, characterized by progressive bodyweight loss and decreased muscle strength, and it significantly increases the risks of morbidity and mortality in the population with atrophy. Numerous complications associated with decreased muscle function can activate catabolism, reduce anabolism, and impair muscle regeneration, leading to muscle wasting. microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), types of non-coding RNAs, are important for regulation of skeletal muscle development. Few studies have specifically identified the roles of miRNAs and lncRNAs in cellular or animal models of muscular atrophy during cachexia, and the pathogenesis of skeletal muscle wasting in cachexia is not entirely understood. To develop potential approaches to improve skeletal muscle mass, strength, and function, a more comprehensive understanding of the known key pathophysiological processes leading to muscular atrophy is needed. In this review, we summarize the known miRNAs, lncRNAs, and corresponding signaling pathways involved in regulating skeletal muscle atrophy in cachexia and other diseases. A comprehensive understanding of the functions and mechanisms of miRNAs and lncRNAs during skeletal muscle wasting in cachexia and other diseases will, therefore, promote therapeutic treatments for muscle atrophy.